IGKV1D-16

Across TCGA pan-cancer cohorts, IGKV1D-16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGKV1D-16 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IGKV1D-16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGKV1D-16 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, GBM, and LUAD are the cancer types where IGKV1D-16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.476	0.901	.022	24	view →
GBM	DFS	Median	All	0.252	0.591	<.001	6	view →
LUAD	OS	Quartile	All	0.936	1.000	.038	2	view →
LSCC	OS	Quartile	All	0.933	1.000	.048	2	view →
CCRCC	DFS	Quartile	All	0.918	0.576	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IGKV1D-16–PDAC (DFS)

Open the PDAC breakdown →